A phase I study of indoximod in patients with advanced malignancies

PURPOSE: Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum tolerated dose (MTD) and toxicity for indoximod in patients with advanced solid tumors. Secondary endpoints included response rates, pharm...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Soliman, Hatem H., Minton, Susan E., Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A., Roberts, John D., Link, Charles, Vahanian, Nicholas N., Mautino, Mario, Streicher, Howard, Sullivan, Daniel M., Antonia, Scott J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Clinical Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5008412/
https://ncbi.nlm.nih.gov/pubmed/27008709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8216
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller